Voisin Consulting Life Sciences (VCLS)’s Post

Amanda Kay, Ph.D., Flagship Senior Partner and Chief Business Development Officer, was joined in the #FlagshipStudio by Repertoire’s John Delyani, Merck’s Lizabeth Leveille, Generate:Biomedicines’s Sahm Nasseri, and Novartis’ Gianfranco De Pascale for a deep dive into early-stage deals between biotech and pharma. Watch the full conversation to hear more about what drives success on both sides of the table, the value of going deep on the science, and the importance of relationship building and trust throughout the process: https://bit.ly/4hnsZJe #JPM25

Next week, Dr. Claudia Hesselmann, PhD and Louis Smikle are heading to San Francisco for the prestigious Biotech Showcase Conference! 🏙️ Why Biotech Showcase? This annual event is a hub for innovation, collaboration, and networking within the biotech and pharmaceutical industries. With hundreds of key decision-makers, thought leaders, and innovators gathering in one place, it’s the perfect platform to discuss groundbreaking advancements and explore new opportunities. 🎯 What to Expect from ARENSIA: Claudia and Louis are thrilled to engage in meaningful conversations about accelerating early-phase clinical trials. They will be sharing insights into ARENSIA’s proven strategies for delivering faster and more cost-efficient trial solutions for the biotech community. 🤝 Let’s Connect! Are you attending the Biotech Showcase? Don’t miss the chance to meet Claudia and Louis in person! Whether you want to learn more about our innovative approach or discuss potential collaborations, they’re excited to connect with you. 📩 Reach out to us to schedule a meeting, we’d love to hear from you! See you in San Francisco! #biotechshowcase #sanfrancisco #arensia #clinicalresearch #clinicaltrials

AdAlta (ASX:1AD) CEO & MD Tim Oldham has just completed a successful US partner and investor roadshow. He presented at Biotech Showcase as part of JPMorgan Healthcare Week in San Francisco and visited San Diego, New York and Boston. It was great opportunity to meet existing and prospective investors and partners and connect with emerging trends in the global biotech sector. BioCentury Intelligence summarised JPMorgan Healthcare Week: “The biopharma innovation emerging from China and Asia was the topic of conversation. From in-licensing to newcos, deals are closing every week — reshaping the global biopharma landscape.” AdAlta’s “East to West” cellular immunotherapy strategy is leveraging the sustained uplift now occurring in biopharma innovation emerging from China and Asia. It is connecting this flow of “Eastern” biopharma innovation with those “Western” companies wanting to access it, big US biopharma groups included. AdAlta hope's to unveil new developments in its evolving “East to West” strategy that is playing to this global trend soon.

The premier biotechnology platform with professionals from the life sciences community ✅ ... for networking, engaging discussions, exploring progresses in research, manufacturing, marketing, data, financing ✅ ... you name it ✅ Swiss Biotech Association #swissbiotechday #swissbiotechday2024

From our series "Marcom’s Favorite Events," Alin, our team's most tech-savvy member, shares his insights on his favorite event in the Pharma industry. Watch until the end to get the full picture of this exciting event!

Insightful discussion on the value of partnerships at Executive Insights 2024 Emphasizing that partnerships are critical for successful drug development, especially for small companies like BioArctic that rely on collaborations, Gunilla Osswald, BioArctic CEO, was one of the speakers at the Executive Insights 2024 conference hosted by Cytel, DNB, and Flerie. Osswald values partners who are truly interested in working together cooperatively to achieve strong relationships and added a sixth "R" to the classic 5R concept in pharma negotiations - focusing on the significance of relationships and their ability to advance innovation. The six Rs: - Right target - Right patient population - Right dose and exposure - Right study design - Right safety - Right collaborations

Collaboration: The powerful leverage in Drug Development BioArctic's post highlighting CEO Gunilla Osswald's revised perspective on AstraZeneca's 5R Framework for successful drug development is spot on. As a scientist with 12 years of experience leading Offspring Biosciences, a Tissue Analytics CRO, as well as previously working on the big pharma side overseeing outsourcing of research, I offer my take on this. Synergy through Collaboration: The Power of the 6th R Gunilla's insightful addition of a 6th "R" – Right Collaboration – to the existing 5R framework is a powerful recognition of the critical value CRO partnerships brings to drug development. Indeed, the CRO industry's tremendous expansion during the past 15 years is a direct reflection of the growing need for specialized expertise in today's complex drug development landscape. Beyond Execution: The Embedded Scientific Partner However, maximizing the value of these collaborations hinges on how they are structured and executed. This is where Gunilla Osswald's concept of "Right Collaboration" comes into play. My experience is that the ideal scenario involves the CRO functioning as a truly embedded scientific partner, actively involved in designing, executing, and evaluating studies that drives the projects forward to the next critical decision point. This collaborative approach stands in contrast to operative models for outsourcing where the CROs serve primarily as an extension of the pharma company's lab, executing tasks with limited input. BioArctic’s 6R framework, with its emphasis on Right Collaborations, paves the way for a more symbiotic relationship which leverages the strengths of both pharma and CRO for an accelerated and successful drug development progress. A Shared Journey As scientists and industry professionals, both within pharma and CROs, we share a common goal: advancing the development of safe and effective drugs that brings true value to our common client – the patients. Let's unlock the power of true collaborations, as outlined in the 6R framework, to turn this vision into reality. What do you think? Share your experiences from collaborative CRO partnerships in the comments! #Collaboration #DrugDevelopment https://lnkd.in/dfPpTRgc https://lnkd.in/dgPX22aV

A few weeks have gone by since our first one-day symposium, ‘Unlocking Early Drug Development’ took place at the Parc Científic de Barcelona, but we’re still buzzing with excitement from the incredible turnout! To everyone who participated, attendees, both in-person and online, speakers and sponsors, thank you for making this event so meaningful. It was inspiring to see so many bright minds come together to share their expertise and explore new possibilities in early drug development. We’ve put together a short video capturing the highlights of the day, which we'll be sharing shortly. If you missed the symposium or want to relive the key moments, stay tuned! And finally, for those companies interested in collaborating on a similar event next year, we’d love to hear your ideas. Whether you’re looking to sponsor, present, or co-organize, let’s explore how we can create another impactful event together. If you have any solid form challenges, remember that our team is ready to help you. Whether it's solid form characterization and screening, crystallization, particle size reduction, or early preclinical formulation development, we’re here to provide tailored solutions to your solid state needs. Thank you all once again for being part of this journey. Here's to pushing the boundaries of early drug development! #symposium #drugdevelopment #innovation #crystallization #partnership

📣The Inbeeo view from Swiss Biotech Day!📣 Christel Jansen and Vincenzo Straccia were representing the Inbeeo team at the Swiss Biotech Association Swiss Biotech Day congress recently as well as visiting nearby clients. We were  both amazed to see first-hand such a breadth of innovation coming from this global Life Sciences hub in the heart of Europe – both very exciting and humbling at the same time. Christel and I had the privilege of meeting with organisations at the beginning of their journeys as well as with leaders from global institutions that are improving lives for people around the world at scale. It was a truly inspirational few days! A further highlight was visiting the Roche Building 1 in Basel (thank you again for the snap Christel!😎).  Your team may be at the point of looking for further investor support, or beginning to consider reimbursement strategy or indeed life cycle optimization. Just as with the vision communicated at Swiss Biotech Day and the views from Building 1, Inbeeo can help you see the bigger picture and what is possible. Want to discuss further? Please don't hesitate to reach out! #marketaccess #drugpricing #pharmaceuticals